RECURSION PHARMACEUTICALS INC. - CLASS A COMMON S

Recursion and Exscientia Shareholders Approve the Proposed Combination

13 Nov 2024 06:08:19 By Nasdaq GlobeNewswire

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden

12 Nov 2024 13:54:03 By Nasdaq GlobeNewswire

Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results

06 Nov 2024 13:15:00 By Nasdaq GlobeNewswire

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

30 Oct 2024 05:22:19 By Nasdaq GlobeNewswire

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

22 Oct 2024 05:00:00 By Nasdaq GlobeNewswire

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

02 Oct 2024 05:00:00 By Nasdaq GlobeNewswire

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

03 Sep 2024 05:00:00 By Nasdaq GlobeNewswire

CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

08 Aug 2024 11:41:34 By Nasdaq GlobeNewswire

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

08 Aug 2024 04:39:25 By Nasdaq GlobeNewswire

Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

08 Aug 2024 04:30:30 By Nasdaq GlobeNewswire

Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT

07 Aug 2024 22:32:39 By Nasdaq GlobeNewswire

Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th

05 Aug 2024 13:01:00 By Nasdaq GlobeNewswire

Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock

26 Jun 2024 19:07:10 By Nasdaq GlobeNewswire

Recursion Announces Proposed Offering of Class A Common Stock

26 Jun 2024 13:06:32 By Nasdaq GlobeNewswire

Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day

24 Jun 2024 05:00:00 By Nasdaq GlobeNewswire

Recursion to Participate in Upcoming Investor Conferences

03 Jun 2024 06:00:00 By Nasdaq GlobeNewswire

Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool

29 May 2024 12:27:37 By Nasdaq GlobeNewswire

Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board

24 May 2024 13:30:00 By Nasdaq GlobeNewswire

Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry

13 May 2024 02:00:00 By Nasdaq GlobeNewswire

Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results

09 May 2024 13:01:00 By Nasdaq GlobeNewswire